Lucy Piper

Bureau Chief at medwireNews

Featured in: Favicon

medwirenews.com Favicon

medicinematters.com (+1) Favicon

springerhealthcare.com

Articles

Mastectomy, salpingo-oophorectomy improve BRCA breast cancer patient survival

1 week ago | medwirenews.com | Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: Risk-reducing surgery leads to improved overall survival for breast cancer patients carrying a BRCA1 or BRCA2 mutation, confirm two studies published in The Lancet Oncology. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © Pradit_Ph / Getty Images / iStock
Support for amiloride as a spironolactone alternative in resistant hypertension

2 weeks ago | medwirenews.com | Lucy Piper

By Lucy Piper, medwireNews ReportermedwireNews: The diuretic amiloride may be a suitable treatment alternative to spironolactone for patients with resistant hypertension, suggests a study published in JAMA. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © Alessandro Grandini / stock.adobe.com
Childhood cancer survivors might benefit from cochlear implants

3 weeks ago | medwirenews.com | Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: Childhood cancer survivors with severe to profound sensorineural hearing loss following chemotherapy or radiotherapy may be candidates for cochlear implants, US researchers believe. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © Sladic / Getty Images / iStock
Agnostic dMMR tumour PD-1 inhibitor approach may avoid resection

1 month ago | medwirenews.com | Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: Patients with deficient mismatch repair cancers may not require surgery after 6 months of neoadjuvant treatment with the PD-1 inhibitor dostarlimab, suggests research published in The New England Journal of Medicine. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © bymuratdeniz / Getty Images / iStock
Lorundrostat shows promise for uncontrolled, treatment-resistant hypertension

1 month ago | medwirenews.com | Lucy Piper

By Lucy Piper, medwireNews ReportermedwireNews: Lorundrostat, a selective aldosterone synthase inhibitor, shows blood pressure-lowering potential in people with uncontrolled and treatment-resistant hypertension, according to the Advance-HTN trial. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © Kurhan / stock.adobe.com
Polygenic risk score may improve prostate cancer screening

1 month ago | medwirenews.com | Lucy Piper

medwireNews: A polygenic risk score could help direct prostate cancer screening towards those at highest risk for the disease, the BARCODE1 investigators report. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © angellodeco / stock.adobe.com
CSF tau may flag hippocampal atrophy in new-onset refractory status epilepticus

1 month ago | medwirenews.com | Lucy Piper

By Lucy Piper, medwireNews ReportermedwireNews: Elevated total tau in cerebral spinal fluid may indicate initial brain injury in patients with cryptogenic new-onset refractory status epilepticus and predict subsequent hippocampal atrophy, suggest study findings. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intensive systolic blood pressure control reduces CVD mortality risk in the over 80s

2 months ago | medwirenews.com | Lucy Piper

By Lucy Piper, medwireNews ReportermedwireNews: Antihypertensive treatment of patients over the age of 80 years to a target systolic blood pressure below 130 mmHg could significantly reduce their risk of death from cardiovascular disease by 26%, suggests an analysis of NHANES data. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © Drazen Zigic / Getty Images / iStock
Half-dose apixaban noninferior for preventing recurrent VTE in cancer patients

2 months ago | medwirenews.com | Lynda Williams |Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: For patients with active cancer and venous thromboembolism, a reduced dose of apixaban is noninferior to the standard dose for preventing recurrent thromboembolic episodes and significantly reduces the risk of clinically relevant bleeding, report the API-CAT investigators. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
‘Accelerated’ onset of aging-related disease highlighted for childhood cancer survivors

2 months ago | medwirenews.com | Lynda Williams |Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: Children who survive for at least 5 years after treatment for cancer are 2.7 times more likely to develop one of eight aging-related chronic health conditions before the age of 65 years than members of the general population, US researchers suggest. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.